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Abstract The process of axonal and dendritic development
establishes the synapticcircuitryofthe central nervous system
(CNS) and is the result of interactions between intrinsic
molecular factors and the external environment. One growth
factorthathas a compelling function inneuronaldevelopment
istheneurotrophinbrain-derivedneurotrophicfactor(BDNF).
BDNF participates in axonal and dendritic differentiation
during embryonic stages of neuronal development, as well as
in the formation and maturation of dendritic spines during
postnatal development. Recent studies have also implicated
vesicular trafficking of BDNF via secretory vesicles, and both
secretory and endosomal trafficking of vesicles containing
synaptic proteins, such as neurotransmitter and neurotrophin
receptors, in the regulation of axonal and dendritic differen-
tiation, and in dendritic spine morphogenesis. Several genes
that are either mutated or deregulated in neurodevelopmental
disorders associated with mental retardation have now been
identified, and several mouse models of these disorders have
been generated and characterized. Interestingly, abnormalities
indendriticandsynapticstructure are consistentlyobservedin
human neurodevelopmental disorders associated with mental
retardation, and in mouse models of these disorders as well.
Abnormalities in dendritic and synaptic differentiation are
thought to underlie altered synaptic function and network
connectivity, thus contributing to the clinical outcome. Here,
we review the roles of BDNF and vesicular trafficking in
axonal and dendritic differentiation in the context of dendritic
and axonal morphological impairments commonly observed
in neurodevelopmental disorders associated with mental
retardation.
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General overview: dendritic spines
Cellular models of associative learning and memory have
shown that enduring activity-driven changes in the efficacy
of synaptic transmission, i.e. synaptic plasticity, initiates
changes in neuronal connectivity, which is reflected in the
formation of new synapses or the structural remodeling of
existing ones. The “hot spot” of this structural plasticity is
the dendritic spine. Dendritic spines are small protrusions
extending from dendrites that are the main postsynaptic site
of excitatory glutamatergic synapses in the brain. Structur-
ally, a spine consists of a spherical head connected by a thin
neck to a parent dendrite (Fig. 1). Spines can vary
structurally owing to changes in their length, the shape of
the head, and the diameter of the neck. Dendritic spines
serve as critical compartments in which biochemical (e.g.
kinases, phosphatases) and ionic (e.g. Ca
2+,N a
+) changes
occur during excitatory synaptic transmission. In addition,
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DOI 10.1007/s11689-009-9027-6the dynamic and plastic nature of spines observed in vitro
[1–3]a n din vivo [4–6] supports the hypothesis that
changes in the shape and number of spines contribute to
the mechanisms of memory formation and storage [7–9].
Indeed, numerous reports have demonstrated that changes
in the morphology or density of spines occur after induction
of synaptic plasticity, e.g. long-term potentiation (LTP) and
long-term depression (LTD), widely accepted cellular
underpinnings of associative learning and memory [10].
The morphology of dendritic spines is thought to play an
important role in determining their function. Simple spines
are characterized by three major types: stubby (type-I)
spines have no obvious neck, mushroom (type-II) spines
have a large head that is connected to the parent dendrite by
a narrow neck, while thin (type-III) spines have a small
head connected to the dendrite by a long neck [11]. Mature
spines are thought to originate during development from
dendritic filopodia, long thin processes that emanate from
the dendrite, which after contact with an axon, initiate
spinogenesis and synaptogenesis. Recent work has demon-
strated that dendritic spine morphology modulates Ca
2+
entry into the spine and diffusion through the spine to the
parent dendrite [12, 13], synaptic transmission [14],
synapse formation [15] and spine stability [16, 17].
Furthermore, in vivo evidence in mice and rats demonstrate
that in response to environmental manipulations and
learning, spine density and morphology are both altered
[18]. More recent evidence also indicates that changes in
the molecular composition of dendritic spines are initiated
during learning. Matsuo et al. observed that newly
synthesized GluR1 AMPA receptors are recruited directly
to mushroom-shaped spines in the hippocampus 24 hrs
after fear conditioning [19].
What molecular cue initiates these structural modifica-
tions during synaptic plasticity? Given that ionotropic
glutamate receptors are highly expressed at the postsynaptic
density (PSD) of dendritic spines, it is not surprising that
ligands of these receptors modify spine density and
morphology [20]. However, the release of glutamate into
the synaptic cleft is extremely rapid, so activation of
glutamate receptors must also recruit/regulate additional
signaling components that can lead to sustained structural
modifications of spines that occur for long periods. The
chemical signal that would alter the number or structure of
Fig. 1 The structure of dendritic spines of hippocampal pyramidal
neurons. Using particle-mediated gene transfer (a.k.a. gene gun),
organotypic slice cultures were transfected with cDNA coding for
eYFP. Top panels: Laser-scanning confocal microscopy images of a
pyramidal neuron in area CA1 are shown at different magnifications to
illustrate the complexity of their dendritic arbor and the abundance of
dendritic spines in secondary and tertiary branches. Bottom left panel:
A maximum-intensity projection of z-stacks shows a dendritic
segment studded with the most common spine morphologies, i.e.
stubby, mushroom and thin. The cartoon illustrates the geometrical
dimensions measured in individual spines to categorize them (adapted
from Ref. 32). Bottom right panel: A mushroom dendritic spine
(outlined in green) forms an asymmetric synapse with a single
presynaptic terminal (outlined in red) in stratum radiatum of area
CA1 in organotypic slice culture
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order for these adjustments to contribute to the process of
synaptic plasticity. Thus, this molecular cue would need to
be released by some type of plasticity-inducible stimuli,
contribute to the process of synaptic plasticity and learning
and memory, and be able to modify dendritic spine by
itself.
The role of BDNF in dendrite differentiation
and dendritic spine formation and plasticity
The mammalian neurotrophins, nerve growth factor (NGF),
BDNF, neurotrophin-3 (NT-3), and neurotrophin 4/5
(NT-4/5) have essential roles in neuronal survival and
differentiation [21]. BDNF is produced initially as a
precursor form, a pro-neurotrophin (30–35 kDa), before it
is proteolytically cleaved into a mature neurotrophin form
(12–13 kDa). In addition, neurotrophins in general and
BDNF in particular, are strong modulators of synaptic
transmission and plasticity [18, 22–26]. Anatomically,
BDNF levels in the hippocampus, a brain region important
for learning and memory, are amongst the highest in the
brain [27]. Functionally, long-term exposure to BDNF
increases spine density in CA1 pyramidal neurons in rodent
hippocampus, an effect that is blocked by the tyrosine
kinase inhibitor k-252a, suggesting that the spinogenic
effect of BDNF is mediated by the tyrosine kinase activity
of the high affinity BDNF receptor, TrkB [28].
BDNF mediate its effect by the binding to one of two
different families of receptors: the pan-neurotrophin
receptor p75
NTR, which is a member of the tumor necrosis
family of receptors, and a specific tyrosine kinase receptor
[29, 30]. Binding of mature BDNF dimers to the TrkB
receptor causes receptor dimerization and autophosphor-
ylation in the tyrosine residues that form platforms for
adaptor protein binding, leading to the activation of
phosphatidylinositol 3-kinase (PI3K), mitogen-activated
protein kinase (MAPK, also ERK) and phospholipase C-γ
(PLC-γ) signaling cascades [31]. BDNF-induced spine
formation requires activation of at least two of these
signaling cascades. Inhibitors of the MEK1, which prevent
further signaling through the MAPK/ERK signaling
cascade, prevented BDNF-induced spinogenesis [32],
while functional TRPC channels, which are activated by
the PLC-γ cascade [26, 33] and cAMP signaling, are also
necessary for BDNF to enhance dendritic spine density
[34, 35]. In contrast, the effect of BDNF-induced
modulation of dendritic spines by p75
NTR remains under
intense investigation in several labs [36, 37].
In addition to its spinogenic effects, BDNF also
increases the proportion of mature and stable stubby spines
under conditions of both action potential-dependent and -
independent synaptic transmission [38]. In contrast, when
SNARE-dependent vesicular synaptic transmission is
abolished with Botulinum neurotoxin C, BDNF increases
the proportion of the highly unstable and immature thin
type spines [38]. These data suggest that not only does
long-term exposure to BDNF induce new spine formation
regardless of neuronal activity levels, but BDNF also
works together with neurotransmitter release [39]t o
modulate spine morphology. The role for BDNF in
activity-dependent functional plasticity of excitatory glu-
tamatergic synapses is further supported by the observa-
tion that release of endogenous (native) mature BDNF
occurs in response to afferent stimulus patterns known to
be effective for neuropeptide release from dense-core
vesicles and to induce synaptic plasticity [40–43]. It
should be noted that whether and under what circum-
stances the BDNF precursor, proBDNF, is secreted by
neurons remain unclear [44]; but see [45, 46]. A differential
modulation of dendritic spine density and morphology by
proBDNF vs. mature BDNF, as proposed for synaptic
plasticity [47], will certainly expand the already extensive
repertoire of this multifaceted neurotrophin.
It has been suggested that thin spines are “learning
spines” because they are constantly changing in response to
activity, while mushroom spines are “memory spines”
because they are highly stable structures [48]. Intriguingly,
hippocampal slice cultures maintained in serum-containing
media, which has a lower p75
NTR-to-TrkB expression
levels than hippocampal slice cultures maintained in the
previously published serum-free media [38], BDNF not
only increased spine density, but also shifted the propor-
tions of spines towards the “learning” (thin) and “memory”
(mushroom) shaped spines [49]. Together with observations
in p75
NTR knockout mice [37], these results suggest a
potential opposite effect of TrkB and p75
NTR signaling on
the morphology of dendritic spines, as another example of
the “Yin-Yang” of neurotrophin receptor signaling [47].
Furthermore, the enlargement of spine head volume and
“spine twitching” caused by repetitive pairing of two-
photon glutamate uncaging onto single spines and postsyn-
aptic action potentials is mediated by release of endogenous
BDNF [50]. Though it is still unknown whether it mediates
activity-dependent dendritic spine plasticity during learning
and memory in vivo, BDNF is a strong candidate as an
inducible factor that structurally prepares excitatory synap-
ses for consolidation of hippocampal-dependent learning
[24]. Does BDNF-induced structural plasticity of dendritic
spines have functional consequences? At least for intracel-
lular Ca
2+ signaling, the shift towards a higher proportion
of mature shaped spines after BDNF exposure promotes
supralinear Ca
2+ elevations in oblique dendrites of CA1
pyramidal neurons during coincident pre and postsynaptic
activity [51].
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serve as a critical molecular cue that contributes to activity-
dependent structural plasticity of dendritic spines [18].
BDNF-induced modifications in dendritic architecture
including spine density and morphology, along with its
modulation of presynaptic neurotransmitter release [39, 52],
likely underlie the role of BDNF in the establishment and
connectivity of the neuronal network required for synaptic
plasticity and hippocampal-dependent learning and memory
[24, 26, 53].
Dendritic pathologies in neurodevelopmental disorders
associated with mental retardation
Neurodevelopmental disorders associated with mental
retardation are characterized by a prevalent deficit in
cognitive function and behavioral adaptations that range
in severity and are often accompanied with symptoms
specific to each disorder. Mental retardation-associated
disorders that have an environmental or genetic origin
have long been associated with morphological pathologies
of dendrites and spines [54, 55]. Pioneering studies by
Huttenlocher, Marin-Padilla, and Purpura published in the
1970’s described abnormalities in the dendritic morphol-
ogy of cortical neurons obtained from postmortem brain
samples [56–61]. The abnormalities in dendritic structure
included an overall reduction in dendritic spine numbers
or the prevalence of long and thin spines (sometimes
called tortuous spines), a cellular neuropathology termed
“spine dysgenesis” [59]. While the results between reports
varied as to the exact morphologically aberrations
detected, the results consistently demonstrated abnormal
dendritic structure.
These findings provide a morphological basis for the
proposed synaptic deficiencies thought to underlie mental
retardation, whereby smaller spine head sizes and lower
spine density results in a reduction in postsynaptic surface
area, leading to impaired excitatory neurotransmission
and activity-dependent Ca
2+ influx. Since those initial
observations, reduced dendritic complexity, as well as
significant differences in dendritic spine numbers and
morphological spine types, have been described in several
mental retardation-associated disorders, ranging from
environmental (e.g. fetal alcohol syndrome or lead
exposure), to autosomal genetic (e.g. Down syndrome),
to X chromosome linked origins (e.g. Rett syndrome,
fragile-X syndrome) [54, 55, 62]. Identifying the specific
dendritic pathologies in every mental retardation syn-
dromes will provide a deeper understanding of the
underlying structural and molecular dysfunction causing
these disorders. Below, we will describe the spine and
synaptic abnormalities reported for Rett syndrome, a
neurodevelopmental disorder associated with mental re-
tardation. While this disease will be specifically discussed,
it should be noted that many other neurological diseases
and neurodevelopmental disorders have been shown to
have altered dendritic spine structure [55].
Rett syndrome
A neurodevelopmental disorder associated with mental
retardation and presenting with “spine dysgenesis” in
cortical neurons is Rett syndrome (RTT). RTT is an X
chromosome-linked disorder that affects approximately
1:15,000 females worldwide, without predisposition to
any particular racial or ethnic group. Birth and the normal
milestones of early development (e.g. growth patterns,
motor, language and social skills) appear uneventful in
individuals with RTT until approximately 6–18 months.
Furthermore, features demonstrating signs and symptoms of
autism, have also be observed in some individuals afflicted
with RTT [63].
Mutations in MECP2, the gene encoding methyl-CpG-
binding protein-2, have been identified in >80% of RTT
individuals [64, 65]. MeCP2 is a DNA-binding protein with
high affinity for A/T rich sites in close proximity to
methylated CpG islands, recruiting co-repressors and
histone deacetylase complexes, thereby altering the struc-
ture of genomic DNA and repressing the transcription of
specific target genes [66–69]. The brain pathology of RTT
includes reduced neuronal size and increased cell density in
several brain regions including the cerebral cortex, hypo-
thalamus and the hippocampal formation [70, 71]. Reduced
dendritic tree size and complexity in pyramidal cells was
observed in the frontal and motor cortices and in the
subiculum, the main output region of the hippocampal
formation [72]. Furthermore, reduced levels of microtubule-
associated protein-2 (MAP-2), a protein involved in
microtubule stabilization, were found throughout the
neocortex of RTT autopsy material [73–75]. Lastly, reduced
dendritic spine density and expression of cyclooxygenase, a
protein enriched in dendritic spines, was reported in the
cortex of RTT individuals [74, 76, 77]. These observations
support the hypothesis that RTT is caused by impaired
development that altered activity-dependent refinement of
synaptic connections [78–80].
Observations regarding dendritic and synaptic pathol-
ogies in experimental animal models of Rett syndrome
have produced varied results. However, impairments in
excitatory synaptic transmission and common neurologi-
cal phenotypes that are reminiscent of several RTT
s y m p t o m sa r ec o n s i s t e n ta c r o s st h et h r e em o u s em o d e l s
of RTT based on MeCP2 loss-of-function. Two of the
RTT models are full deletions of Mecp2 ([81]e x o n3
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deletions, a.k.a. Bird null mice), and one mouse model
contains a premature stop codon after codon 308 that
yields a non-functional truncated protein (Mecp2
308 [83]).
Though the genetic backgrounds and extent of MeCP2
deficiencies in these mouse lines are different, they all
show delayed onset of symptoms (approximately 5 weeks
of age), which included motor impairment and abnormal
gait. Mecp2 null mice have hind-limb impairments, while
Mecp2
308 mice show forelimb impairments [83, 84]. In
addition, excitatory (but not inhibitory) synaptic transmis-
sion onto cortical pyramidal neurons is impaired in Mecp2
null mice [85], as well as between cultured Mecp2-
deficient hippocampal neurons [86].
Consistent with impairments of glutamatergic synaptic
transmission, deficits in hippocampal synaptic plasticity
and hippocampal-dependent learning and memory were
observed in Mecp2 null mice [87] and Mecp2
308 mice [88].
Intriguingly, overexpression of MeCP2 also led to neuro-
logical abnormalities. Transgenic mice expressing one copy
of the human MECP2 gene with all regulatory elements
(which approximately doubled MeCP2 protein levels),
initially showed a higher learning performance and en-
hanced hippocampal LTP, though seizures and other
symptoms developed after 20 weeks of age and death
occurred shortly thereafter [89]. Micro-island cell cultures
of hippocampal neurons from Mecp2 overexpressing mice
formed more excitatory autapses compared to wildtype
neurons, while the opposite was observed in cultures from
Mecp2-deficient mice [90]. In contrast, a five-fold increase
in MeCP2 levels did not affect dendritic spine density in
hippocampal pyramidal neurons maintained in slice culture,
but did show a significant increase in dendritic spine length
[91]. Recent evidence gives more precedent that altered
expression of MeCP2 lead to a reduction in dendritic spine
number. Dendritic spine density is reduced throughout the
brain of Mecp2 knockout mice, with a great deficiency
observed in the CA1 region of the hippocampus [92, 93]a
phenotype also observed in humans individuals with RTT
[77]. Cortical and hippocampal pyramidal neurons from
Mecp2
308 mice did not show any dendritic or synaptic
morphological pathology, despite significant impairments
in hippocampal-dependent learning and memory, as well as
hippocampal synaptic plasticity [88]. In contrast, Mecp2
knockout mice have smaller and less complex pyramidal
neurons in cortical layers II/III, while no differences in
spine density were reported at 8 weeks of age [94]. In the
somatosensory cortex of Mecp2 null mice, pyramidal
neurons showed lower spine density and reduced dendritic
branching by 6 weeks of age [95].
It has been suggested that these reduced numbers of
excitatory synapses reflect delayed neuronal maturation,
since newly born neurons in the adult dentate gyrus have
lower dendritic spine density than their mature neighboring
neurons [96]. Consistent with such role in neuronal
differentiation, NGF-induced neurite outgrowth in PC12
cells was inhibited by Mecp2 knockdown with antisense
oligonucleotides [97]. On the other hand, Mecp2 over-
expression increased the complexity and length of axons
and dendrites in primary cortical neurons, while over-
expressing Mecp2 with a truncation at the C-terminal
(Mecp
293) increased axonal and dendritic branching without
affecting their overall length [98]. New evidence suggests
that the abnormalities in dendritic structure in Mecp2
deficient neurons (cultured from knockout mice) are a
result of the release of toxicity substances from neighboring
Mecp2 deficient astrocytic cells [99, 100]. Taken altogether,
observations in Mecp2-based mouse models, as well as
overexpression and knockdown experiments in cultured
neurons and brain slices support the hypothesis that Rett
syndrome is caused by impaired growth and activity-
dependent maturation of pyramidal neuron dendrites, axons
and their excitatory synapses, leading to deranged synaptic
transmission and plasticity. Thus, specific neurological
symptoms arising from impaired functioning of improperly
wired neuronal networks in specific brain regions, likely
cause defects in activity-dependent synaptic strengthening
and pruning during postnatal development.
Four experimental approaches have been shown to
reverse severe impairments in symptomatic Mecp2 null
mice, two based on gene expression manipulations, and two
by pharmacological treatments. The overexpression of Bdnf
in postnatal forebrain neurons under control of the CaMKII
promoter extended the lifespan, rescued a locomotor defect,
and reversed an electrophysiological deficit observed in
Mecp2 null mice [101]. The overexpression of the Bdnf
gene in primary hippocampal cultures fully rescued the
dendritic atrophy caused initiated by endogenous Mecp2
knockdown [102]. However, when Bdnf was overexpressed
in neurons that were transfected with RTT-associated
MECP2 mutants, only a partial rescue of the dendritic
phenotype occurred [102]. The potential target of BDNF
expression as a therapeutic approach to alleviate RTT
symptoms is further supported by the reversal of breathing
pattern irregularities in Mecp2 null mice by treatment with
an AMPAkine [103], a family of allosteric modulators of
AMPA-type glutamate receptors known to enhance BDNF
mRNA and protein levels [104, 105]. Supporting the
potential use of trophic factors to reverse the RTT-like
impairments in Mecp2 null mice, an active peptide
fragment of Insulin-like Growth Factor 1 (IGF-1) extended
the lifespan, improved locomotor function, ameliorated
breathing patterns, reduced heart rate irregularity, and
increased brain weight. Furthermore, IGF-1 partially re-
stored dendritic spine density and excitatory synaptic
current amplitude, the expression of the synaptic scaffold-
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Mecp2 null mice to wild-type levels [106]. Finally, in a
proof-of-concept experiment that demonstrates that severe
impairments in symptomatic Mecp2 null mice can be
reversed, the re-expression of the Mecp2 gene under control
of its endogenous promoter extended the lifespan and
prevented the advanced neurological symptoms [107].
Altogether, these successful therapeutic approaches that
reversed RTT-like symptoms in Mecp2 null mice provide
further support to the potential pharmacological reversal of
neurodevelopmental disorders in adults [108].
The elusive link between MeCP2 and BDNF
in the pathogenesis of Rett syndrome
The molecular pathway(s) contributing to the pathogenesis
of Rett syndrome (RTT) remain unclear. Since MeCP2 is a
transcriptional regulator, identifying the genes under its
control will clarify the pathogenesis of RTT and have a
profound impact for the development of therapies. While
many genes have been shown to be regulated by MeCP2
[109], their contributions to the manifestation of the RTT
remains unknown [110–112]. Using gene-target
approaches, two studies identified Bdnf as a target of
MeCP2 transcriptional control [113, 114]. BDNF mRNA
levels are diminished in Mecp2 null mice [101]. Similarly,
BDNF mRNA levels are lower in brain samples from RTT
patients [115, 116]. However, while nerve growth factor
(NGF) was found to be reduced in either blood serum or
cerebral spinal fluid from RTT patients, differences in
BDNF levels were not detected [117–120].
The Chen et al. and Martinowich et al. studies [113,
114] that proposed a mechanistic link between MeCP2 and
BDNF, demonstrated that MeCP2 binds to and represses
the transcription of mouse Bdnf promoter IV, which is
activated by neuronal activity and Ca
2+ influx [121].
Cortical neurons cultured in the absence of neuronal
activity (i.e. in the presence of TTX) from Mecp2 null
mice showed a 2-fold higher level of Bdnf exon IV
transcript compared to neurons from wildtype mice [113].
This result may predict that BDNF levels should be
elevated when Mecp2 is missing or mutated. However,
BDNF protein levels were found to be lower in the brains
of Mecp2 knockout mice at 6–8 weeks of age compared to
wildtype littermates [101]. Furthermore, conditional dele-
tion of the Bdnf in the forebrain of Mecp2 null mice
exacerbated the onset of the RTT-associated phenotypes of
the Mecp2 null animals. And consistently, overexpression
of Bdnf in the forebrain slowed the disease progression
phenotype in Mecp2 null mice [101].
The link between MeCP2 and BDNF appears to be more
complex than originally described. A recent study shows
that Mecp2 overexpression in cultured neurons increases
Bdnf mRNA levels through a homeostatic mechanism
involving miR132, a BDNF-inducible microRNA that
inhibits Mecp2 expression [122]. Despite the identification
of this intriguing microRNA feedback loop, the specific
underlying mechanisms and whether a deregulation of such
mechanisms contribute to the disease pathology of RTT
remain unclear. Furthermore, the relationship between
MeCP2 and BDNF may vary in different brain regions. A
recent microarray study comparing hypothalamic samples
from Mecp2 null and Mecp2 overexpressing mice found
that BDNF mRNA levels were lower in the absence of
Mecp2 and higher when MeCP2 levels were doubled [123].
The challenge ahead is to identify specific clinical
symptoms with affected brain regions, paving the way to
the reversal of life-threatening impairments by region-
specific manipulations of MeCP2 target genes.
Vesicle trafficking, BDNF and Rett syndrome
The proper secretory trafficking of BDNF appears to be
critical for its function in neuronal development and
synaptic plasticity. A common single nucleotide polymor-
phism in the BDNF gene, resulting in a valine to
methionine substitution in codon 66 of the proBDNF
domain (Val66Met), is associated with reduced hippocam-
pal volume, memory impairment and susceptibility to
psychiatric disorders in humans who are heterozygous for
this variant BDNF gene [124]. The substitution of valine to
methionine in the BDNF gene impairs the intracellular
trafficking of the protein and the regulated secretion of
BDNF from hippocampal neurons in culture [125]. Con-
sistently, Val66Met knockin mice have reduced dendritic
branching in dentate granule cells, suggesting that main-
taining the trafficking of BDNF is necessary for the
establishment of dendritic branching [126]. The importance
of BDNF in RTT severity has come into question recently
by two observations that have been described in individuals
afflicted with RTT in addition to carrying the polymor-
phisms of the BDNF Val66Met gene. It has been described
by clinical studies that the Val66Met polymorphisms might
be neuroprotective in RTT, where girls with RTT and
carrying the wildtype BDNF gene demonstrated seizures
earlier in life than girls who with the Val66Met polymor-
phism [127]. While this polymorphism might be neuro-
protective in terms seizure onset, individuals with the
Val66Met polymorphism tended to possess severe pheno-
typic characteristics of the RTT compared to individuals
without the polymorphism [128].
The endosomal trafficking pathway is involved in
delivery of proteins to intracellular compartments and
internalization, recycling and degradation of plasma mem-
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neurons internalize BDNF bound to its receptor in a
clathrin-dependent manner. Proteins delivered to the endo-
somal pathway from the secretory pathway or via endocy-
tosis from the plasma membrane can take three different
route of signaling. They can be either sorted in the early
endosome, recycled, or sent for lysosomal degradation via
the late endosome. In neurons, recycling endosomes and
early endosomes, which have been identified in dendritic
spines, are proposed to allow membrane proteins to recycle
locally within the spine [132, 133]. Recently it was reported
that collapse of the recycling endosome results in a
decrease in spine density in an activity-dependent manner
[133]. Recent reports have demonstrated that proteins
involved in endosomal trafficking as candidate gene
products in some patients with autism. For example, a
haploinsufficiency of RAB11FIP5 was described in one
patient. Rab11FIP5 is a Rab effector involved in protein
trafficking from the recycling endosome to the plasma
membrane and in neurotransmitter release and receptor
recycling [134].
In the secretory pathwaym e m b r a n ep r o t e i n sa n d
secreted cargo are synthesized in the endoplasmic reticulum
(ER), trafficked through the Golgi, and are packaged into
vesicles at the trans-Golgi network (TGN) [131, 135].
Vesicles traffic to endosomes, lysosomes, or the plasma
membrane, where they undergo constitutive or calcium-
dependent, regulated secretion. In neurons regulated secre-
tory vesicles, called secretory granules (SGs) or dense core
vesicles (DCVs), are involved in the packaging, processing
and release neuropeptides, neurotrophins, and biogenic
amines [135–138]. Neuropeptides and neurotrophins like
BDNF, are packaged and processed from pro-forms in
immature secretory granules (ISGs) via proteolytic cleavage
by peptidases, to generate their active mature forms, which
undergo maturation to mature secretory granules (MSGs)
that can undergo exocytosis in response to increases in
intracellular Ca
2+ concentration [139–142]. The Mecp2
knockout mouse model of Rett syndrome demonstrate
abnormal secretory granule exocytosis, with increased
catecholamine release at low frequency stimulation and
exacerbated release at high frequency, suggesting a larger
readily releasable pool of catecholamine containing secre-
tory granules [143].
Understanding the unknown: a link to autism spectrum
disorders
Many neurodevelopmental disorders associated with mental
retardation, such as RTT and fragile X, show comorbidity
with autism spectrum disorders (ASD). ASDs, which
include autism, Asperger syndrome, and pervasive devel-
opmental disorders not otherwise specified (PDDNOS), are
characterized by deficits in social interaction and commu-
nication. ASDs are thought to involve the interaction of
multiple gene variants with environmental factors that
contribute to disruption of normal brain development. Of
the genes implicated in autism, those most pertinent to this
review are BDNF and components of the BDNF signaling
cascade [144, 145]. Indeed, alterations in BDNF levels
have been reported in autism [145, 146]. Downstream of
BDNF, enzymes that regulate the synthesis and degradation
of the signaling phospholipid phosphoinositide-3,4,5-P3
(PIP3) have been implicated in autism, including the genes
encoding the PI3K catalytic p110 subunit PIK3CG, the
Ras-GAP NF1 (Ras is an activator of p110), the inositol
phosphate phosphatase INPP1, and the PIP3 3’ phosphatase
PTEN. Human genetic studies have identified polymor-
phisms in the PTEN locus that are associated with macro-
cephaly and autistic behaviors [147]. Moreover, mice
created with conditional Pten knockout in the cortex and
dentate gyrus, resulted in reduced social interactions,
increased activity in novel environments, impaired senso-
rimotor gating, in addition to macrocephaly and alterations
in spine density and morphology [147].
Several genes downstream of BDNF in the PI3K cascade,
such asTSC1/2 and Centaurin gamma-2 (CENG2), have also
been identified as autism susceptibility genes. Mutations in
TSC1 and TSC2 in humans cause tuberous sclerosis, a
syndrome associated with an increased incidence of autism.
TSC1 and TSC2 are phosphorylated and regulated by the
protein kinase Akt, which is regulated by PIP3. In a mouse
model of tuberous sclerosis, conditional loss of Tsc1 resulted
in enhanced cortical excitability, enlarged neurons in the
cortex and hippocampus, and seizures [148].
Sheffield et al. identified three subjects with ASD with a
deletion in the region of chromosome 2q37.3 where the
CENG2 is located [149]. Analysis of another cohort of
autism subjects revealed several variants of the CENG2
gene, including a variant in the Arf-GAP domain predicted
to lead to a loss of GAP activity. In a recent study, 10% of
autism patients showed copy number variations, as esti-
mated by comparative genomic hybridization on genomic
DNA of ~100 patients; two of them were identified with
2q37.3 deletions [150]. CENG2 has emerged as an
intriguing candidate among the deleted genes because of
its brain mRNA expression pattern and potential role in
regulation of endosomal trafficking and dendritic spine
density (Larimore et al. submitted).
Finally, it is intriguing in the context of BDNF and
vesicle trafficking, that deletion of Caps2,t h eC a
2+-
dependent activator protein for secretion, results in
autistic-like behavioral features [151]. CAPS2 mediates
the exocytosis of dense core vesicles in neurons. Over-
expression of Caps2p enhances NT-3 and BDNF release
J Neurodevelop Disord (2009) 1:185–196 191from PC12 cells and cultured granule cells [152]. Con-
versely BDNF release is impaired in Caps2 knockout
mouse [153], consistent with the possibility that deregu-
lated trafficking and release of BDNF-containing DCVs
may contribute to autism. Indeed, altered levels of BDNF
have been consistently found in serum of individuals with
autism [145, 154–157]. In summary, studies support links
between the deregulation of intracellular vesicular traffick-
ing and signaling pathways downstream of BDNF to
neurodevelopmental disorders associated with mental retar-
dation and autistic-like behaviors.
Final considerations
Here, we have reviewed the evidence that proper axonal
and dendritic development is a fundamental process for the
establishment of synaptic circuitry, and that it results from
complex interactions between intrinsic molecular factors
and the external environment. Among those molecular
factors relevant for activity-dependent neuronal develop-
ment, BDNF stands out as critical player, not only for its
role in normal development but also for the multiple links
to neurodevelopmental disorders associated with mental
retardation and autism spectrum disorders. Indeed, deregu-
lation of any step in BDNF synthesis and release (i.e.
transcription, translation, vesicular packaging, processing
and trafficking, Ca
2+-dependent regulated release, and
signaling) may result in improper axonal, dendritic and
synaptic development, as well as impaired activity-
dependent refinement of synaptic connections during brain
development. Likewise, altered synaptic plasticity in corti-
cal and limbic regions (e.g. hippocampus, amygdala) may
also underlie the cognitive and behavioral adaptation
deficits observed in neurodevelopmental disorders associ-
ated with mental retardation and autism. Since specific
neurological symptoms arise from impaired functioning of
improperly wired neuronal networks in specific brain
regions (likely caused by defective activity-dependent
synapse strengthening and pruning during postnatal devel-
opment), the challenge ahead is to develop rational
therapeutic approaches for the reversal of life-threatening
impairments by region-specific manipulations of specific
intracellular signaling cascades. Indeed, such pharmacolog-
ical reversal of neurodevelopmental disorders in adults has
been demonstrated in several animal models [108].
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